BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Policy

  FDA Sets Adcomm for BMS, J&J CAR T Therapies Amid Class-Wide Safety Concerns

  The FDA’s Oncologic Drugs Advisory Committee will meet on March 15 to discuss BMS and J&J applications for their CAR T-cell therapies Abecma and Carvykti, respectively.

  February 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Regeneron Looks to Target Weight Loss Market with Muscle-Preserving Antibodies

  The biotech is taking a synergistic approach to obesity with two muscle-preserving antibodies set to enter a Phase II study in mid-2024 in combination with existing incretin-based treatments.

  February 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Novo Holdings Buys CDMO Catalent for $16.5B to Boost Semaglutide Supply

  The investment arm of the Novo Nordisk Foundation is acquiring contract development and manufacturing organization Catalent to help meet high demand for Ozempic and Wegovy.

  February 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  4DMT’s Experimental Gene Therapy Cuts Eylea Use in Phase II Wet AMD Trial

  Topline results from a mid-stage study show that 4D Molecular Therapeutics’ investigational gene therapy cut annual rates of Eylea injections by 85% and 89% for the low and high doses, respectively.

  February 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Career Advice

  Academia vs. Industry: Differences in Workplace Culture

  Academic and industry jobs are distinguished by their approaches to collaboration and exploratory research, among other factors.

  February 5, 2024

   · 

  5 min read

   · 

  Sanjukta Mondal
• 

  Deals

  Genome Editing Biotech Metagenomi Targets IPO to Raise $86.9M

  Metagenomi could potentially raise over $100 million if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $16 per share.

  February 5, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Drug Development

  Amgen’s Weight-Loss Drug Candidate Shows Promise in Early Data

  Phase I results published Monday suggest Amgen’s investigational weight-loss drug MariTide produces longer-lasting effects than GLP-1s currently on the market.

  February 5, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• Pharm Country

  Cencora Prices $500 Million 5.125% Senior Notes Due 2034

  Cencora, Inc. announced that it priced $500 million aggregate principal amount of its 5.125% Senior Notes due 2034, in an underwritten registered public offering.

  February 5, 2024

   · 

  4 min read
• Biotech Beach

  Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

  Immix Biopharma, Inc. announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common stock.

  February 5, 2024

   · 

  3 min read
• Business

  Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023

  BioArctic AB’s partner Eisai issued their quarterly report containing Leqembi sales for the fourth quarter 2023.

  February 5, 2024

   · 

  5 min read